CDK4/6抑制剂在乳腺癌治疗中的研究进展

Research progress of CDK4/6 inhibitors in the treatment of breast cancer

CDK4/6抑制剂与内分泌治疗的组合策略被越来越多地应用于晚期乳腺癌患者的治疗中。然而,CDK4/6抑制剂不仅仅用于ER阳性、HER2阴性晚期乳腺癌患者的治疗中,其研究应用也扩展到了其他的乳腺癌类型中。本文旨在阐述CDK4/6抑制剂的耐药机制和进展后的后续治疗,以及其在三阴性乳腺癌、HER2阳性乳腺癌、肿瘤免疫和生活质量中的研究进展。

The combinatorial strategy of CDK4/6 inhibitors and ET are increasingly used in the treatment of patients with advanced breast cancer.However,CDK4/6 inhibitors are not only used in patients with ER positive,HER2 negative advanced breast cancer,but also extended to other types of breast cancer.This article aims to illustrate the drug resistance of CDK4/6 inhibitors and subsequent treatment after progression,as well as its research progression in triple negative breast cancer,HER2 positive breast cancer,tumor immunity and quality of life.